Aristolochia yunnanensis

DOI:

10.1186/s13002-024-00656-1

PubMed:

38395900

Germacrane Sesquiterpenoids as a New Type of Anticardiac Fibrosis Agent Targeting Transforming Growth Factor β Type I Receptor.

Lou LL et al (2019).

J Med Chem.

DOI:

10.1021/acs.jmedchem.9b00708

PubMed:

31408333

(+)-Isobicyclogermacrenal and spathulenol from Aristolochia yunnanensis alleviate cardiac fibrosis by inhibiting transforming growth factor β/small mother against decapentaplegic signaling pathway.

Lou LL et al (2019).

Phytother Res.

DOI:

10.1002/ptr.6219

PubMed:

30375049

Aristoyunnolin H attenuates extracellular matrix secretion in cardiac fibroblasts by inhibiting calcium influx.

Chen SR et al (2017).

Arch Pharm Res.

DOI:

10.1007/s12272-016-0843-4

PubMed:

27704335

Determination of the absolute stereochemistry of two new aristophyllene sesquiterpenes: a combined theoretical and experimental investigation.

Wu RB et al (2014).

Chirality.

PubMed:

24677243

Inhibitory effect of ethyl acetate extract of Aristolochia yunnanensis on cardiac fibrosis through extracellular signal-regulated kinases 1/2 and transforming growth factor β/small mother against decapentaplegic signaling pathways.

Shao W et al (2014).

Transl Res.

DOI:

10.1016/j.trsl.2013.09.013

PubMed:

24157579

Extracellular signal-regulated kinases (ERK) inhibitors from Aristolochia yunnanensis.

Cheng ZB et al (2013).

J Nat Prod.

DOI:

10.1021/np300887d

PubMed:

23570615